New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:55 EDTAEGR, AEGR, TEVA, TEVA, DNDN, DNDN, CELG, CELG, BMRN, BMRN, ALXN, ALXN, BMY, BMY, MYL, MYL, MEIP, MEIP, ISIS, ISIS, GSK, GSK, FMI, FMI, CNAT, CNAT, BLUE, BLUE, XOMA, XOMACowen to host a conference
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 4 at 8:00 am; not all company presentations may be webcasted. Webcast Link
News For AEGR;BLUE;CNAT;FMI;GSK;ISIS;MEIP;MYL;BMY;ALXN;BMRN;CELG;DNDN;TEVA;XOMA From The Last 14 Days
Check below for free stories on AEGR;BLUE;CNAT;FMI;GSK;ISIS;MEIP;MYL;BMY;ALXN;BMRN;CELG;DNDN;TEVA;XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 4, 2014
17:57 EDTBLUEbluebird bio initiated with a Buy at SunTrust
Subscribe for More Information
17:56 EDTCELGCelgene initiated with a Buy at SunTrust
Target $121.
17:56 EDTALXNAlexion initiated with a Buy at SunTrust
Subscribe for More Information
17:17 EDTMYLMylan initiated with a Hold at ISI Group
Subscribe for More Information
17:16 EDTTEVATeva initiated with a Buy at ISI Group
Subscribe for More Information
08:02 EDTTEVA, BMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
07:33 EDTCELGCelgene announces REVLIMID Phase III FIRST trial met primary endpoint
Subscribe for More Information
07:21 EDTTEVAMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
September 3, 2014
19:04 EDTALXNNICE recommends commissioning of Eculizumab for patients with aHUS in England
Subscribe for More Information
05:44 EDTTEVATeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
05:33 EDTCNATConatus management to meet with JMP Securities
Subscribe for More Information
September 2, 2014
19:28 EDTISISIsis Pharmaceutical licensing partner Antisense reports ATL1103 phase II results
Antisense Therapeutics, or ANP, reported the primary efficacy results from its phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I, or sIGF-1, levels of 26% from baseline at week 14 at the 400mg per week dose tested. All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg bodyweight with the patients who received 5.5 mg/kg per week showing a 36% average reduction in their sIGF-I levels. The positive results achieved in this Phase II trial position ATL1103 to move into Phase III stage of development. Consequently, ANP will accelerate out-licencing activities to secure a pharmaceutical development partner for the drug's further development. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals, including ATL1103.
09:41 EDTCELGActive equity options trading on open
Subscribe for More Information
08:31 EDTMEIPMEI Pharma completes enrollment in Phase II clinical trial of pracinostat
Subscribe for More Information
08:19 EDTCELGCelgene GED301 drug has positive risk/reward ratio in near-term, says Bernstein
Bernstein believes that the upcoming trial of Celgene's GED0301 drug for Crohn's disease has very little risk in the near-term, while the presentation of results of a study of the drug next month should be positive for the stock. The firm thinks that the drug could emerge as a popular combination partner for other systemic drugs in patients who continue to have disease symptoms. Bernstein is more cautious about the drug's outlook starting in 2016 but keeps a $103 price target and Outperform rating on the stock.
08:02 EDTTEVATeva reports statistically significant results in reslizumab trial
Teva Pharmaceutical Industries announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations compared to placebo in two pivotal Phase III studies in patients with inadequately controlled moderate to severe asthma with elevated levels of blood eosinophils. In both trials, reslizumab treatment showed both clinically relevant and statistically significant reductions in the frequency of CAE compared to placebo. Reslizumab has also demonstrated a positive effect on lung function and asthma control in the Phase III program . The combination of an effect on clinically important exacerbations and on improvements and preservation of lung function suggest that reslizumab may be a uniquely differentiated treatment for patients with moderate to severe asthma with elevated levels of blood eosinophils. This initial set of results shows the adverse event profile of reslizumab was comparable to placebo in both trials. The incidence of common AEs was consistent with those seen in a moderate to severe asthma population, the most frequent being upper respiratory tract infections, asthma and headache. Further analyses of additional efficacy and safety data are ongoing. These new data are from two global Phase III 12-month, randomized, double-blind, placebo-controlled, parallel-group studies, evaluating the efficacy and safety of intravenously administered reslizumab once every four weeks, compared to placebo in asthma patients that are inadequately controlled by standard of care therapy.
07:15 EDTCNATConatus initiates exploratory Phase 2 trial in cirrhosis patients with PH
Subscribe for More Information
07:12 EDTCNATConatus initiates Phase 2 trial in patients with liver cirrhosis
Subscribe for More Information
07:12 EDTBMYCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
07:10 EDTBMYAlder Biopharmaceuticals regains worldwide rights to clazakizumab
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use